

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced *KRAS*^{G12C} Solid Tumors (KRYSTAL-1)

Sai-Hong Ignatius Ou, MD, PhD¹; Pasi A. Jänne, MD, PhD²; Ticiania A. Leal, MD³; Igor I. Rybkin, MD, PhD⁴; Joshua K. Sabari, MD, PhD⁵; Minal A. Barve, MD⁶; Lyudmila Bazhenova, MD⁷; Melissa L. Johnson, MD⁸; Karen L. Velastegui, BSc⁹; Cornelius Cilliers, PhD⁹; James G. Christensen, PhD⁹; Xiaohong Yan, PhD⁹; Richard C. Chao, MD⁹; and Kyriakos P. Papadopoulos, MD¹⁰

PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of *KRAS*^{G12C}. We report results from a phase I/IB study of adagrasib in non–small-cell lung cancer, colorectal cancer, and other solid tumors harboring the *KRAS*^{G12C} mutation.

MATERIALS AND METHODS Patients with advanced *KRAS*^{G12C}-mutant solid tumors were treated with adagrasib 150 mg orally once daily, 300 mg once daily, 600 mg once daily, 1,200 mg once daily, or 600 mg orally twice a day using an accelerated titration design, which transitioned to a modified toxicity probability interval design when a predefined degree of toxicity was observed or target adagrasib exposure was achieved. Safety, pharmacokinetics, and clinical activity were evaluated.

RESULTS Twenty-five patients were enrolled and received at least one dose of adagrasib. The recommended phase II dose (RP2D) was 600 mg twice a day on the basis of safety, tolerability, and observed pharmacokinetics properties. No maximum tolerated dose was formally defined. After a median follow-up of 19.6 months, eight of 15 patients (53.3%; 95% CI, 26.6 to 78.7) with RECIST-evaluable *KRAS*^{G12C}-mutant non–small-cell lung cancer treated at 600 mg twice a day achieved a confirmed partial response. The median duration of response was 16.4 months (95% CI, 3.1 to not estimable). The median progression-free survival was 11.1 months (95% CI, 2.6 to not estimable). One of two patients with *KRAS*^{G12C}-mutant colorectal cancer treated at 600 mg twice a day achieved a partial response (duration of response, 4.2 months). At the RP2D, the most common treatment-related adverse events (any grade) were nausea (80.0%), diarrhea (70.0%), vomiting (50.0%), and fatigue (45.0%). The most common grade 3-4 treatment-related adverse event was fatigue (15.0%).

CONCLUSION Adagrasib 600 mg twice a day was well tolerated and exhibited antitumor activity in patients with advanced solid tumors harboring the *KRAS*^{G12C} mutation.

J Clin Oncol 40:2530-2538. © 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License 

ASSOCIATED CONTENT

See accompanying article on page 2609

[Data Supplement Protocol](#)

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on January 26, 2022 and published at ascopubs.org/journal/jco on February 15, 2022; DOI <https://doi.org/10.1200/JCO.21.02752>

INTRODUCTION

KRAS is the most frequently mutated *RAS* isoform in cancer, accounting for approximately 85% of *RAS* family mutations observed in human cancers.¹⁻³ In normal cells, *KRAS* proteins cycle between guanosine triphosphate (GTP)-bound on and guanosine diphosphate-bound off states and initiate effector binding and intracellular signal transduction when in the GTP-bound on state.^{1,2} *KRAS* has a protein resynthesis half-life ($t_{1/2}$) of approximately 24 hours.^{1,2} Substitution of Gly12 by cysteine prevents GTP hydrolysis, thereby maintaining *KRAS* in a constitutively active, GTP-bound state; this results in uncontrolled cellular proliferation and growth, as well as malignant

transformation.² *KRAS*^{G12C} mutations occur in approximately 14% of lung adenocarcinomas, 3%-4% of colorectal cancers (CRCs), and 2% of pancreatic cancers.^{1,4,5} The discovery of covalent inhibitors targeting the mutated cysteine residue in *KRAS*^{G12C} within the switch II binding pocket has led to the development of clinically active therapies for patients with tumors harboring the *KRAS*^{G12C} mutation.^{2,6-8}

Adagrasib (MRTX849) is an oral, small-molecule, covalent inhibitor of *KRAS*^{G12C} that irreversibly and selectively binds and locks *KRAS*^{G12C} in its inactive, guanosine diphosphate-bound state.⁹ Adagrasib was optimized for desirable properties of a *KRAS*^{G12C} inhibitor, including high oral bioavailability, long $t_{1/2}$

CONTEXT

Key Objective

This KRYSTAL-1 phase I/IB study reports on the safety, tolerability, recommended phase II dose, and preliminary efficacy of adagrasib, a potent covalent *KRAS*^{G12C} inhibitor, in advanced solid tumors harboring *KRAS*^{G12C} mutation.

Knowledge Generated

The recommended phase II dose of adagrasib is 600 mg orally twice daily. At this dose, eight of 15 patients (53.3%; 95% CI, 26.6 to 78.7) with RECIST-evaluable *KRAS*^{G12C}-mutant non-small-cell lung cancer (NSCLC) and one of two patients with *KRAS*^{G12C}-mutant colorectal cancer achieved a confirmed partial response. Median duration of response and median progression-free survival among patients with *KRAS*^{G12C}-mutant NSCLC were 16.4 months and 11.1 months, respectively.

Relevance

This study provides evidence of robust preliminary clinical efficacy to justify developing adagrasib as a novel *KRAS*^{G12C} inhibitor in patients with *KRAS*^{G12C}-mutant NSCLC and colorectal cancer and potentially those with other advanced tumors harboring *KRAS*^{G12C} mutation.

(approximately 24 hours), extensive tissue distribution, and central nervous system penetration.⁹ In preclinical models, adagrasib demonstrated potent inhibition of *KRAS*-dependent signal transduction (cellular half-maximal inhibitory concentration [IC₅₀]: approximately 5 nM) and cancer cell viability, with > 1,000-fold selectivity for *KRAS*^{G12C} compared with wild-type *KRAS*.⁹ At a fixed dose of 100 mg/kg/day, adagrasib demonstrated broad-spectrum antitumor activity across a panel of *KRAS*^{G12C}-positive lung, colon, pancreatic, and other patient- or cell-derived tumor models implanted in mice.⁹ Additional pharmacokinetics (PK) analysis in these tumor models indicated that maximal and durable antitumor activity was plasma concentration-dependent and dose-dependent and required sustained exposure above a defined threshold to enable inhibition of *KRAS*^{G12C} over the entire dosing interval.^{9,10}

We report results of the phase I/IB dose-finding component of the first-in-human (FIH) KRYSTAL-1 trial, which evaluated the safety, PK, and clinical activity of adagrasib in patients with *KRAS*^{G12C}-mutant advanced solid tumors (ClinicalTrials.gov identifier: [NCT03785249](https://clinicaltrials.gov/ct2/show/study/NCT03785249)).

MATERIALS AND METHODS

Study Objectives

The objectives of this study were to evaluate the safety and tolerability of adagrasib, characterize its plasma PK parameters, determine biologically relevant dose levels, establish the maximum tolerated dose, identify the recommended phase II dose (RP2D), and assess its clinical activity in patients with advanced *KRAS*^{G12C}-mutant solid tumors.

Dose-Escalation Segment Design

The dose-escalation portion of the study used two consecutive phase I designs. The study began with an accelerated titration (AT) design, which transitioned to a

modified toxicity probability interval (mTPI) design when a predefined degree of toxicity was observed or target adagrasib exposure was achieved. The AT design was used to limit the number of patients treated at potentially sub-therapeutic doses during the dose-escalation segment. For any specific regimen, the maximum tolerated dose was defined as the dose associated with the probability of dose-limiting toxicity (DLT) occurring in 30% of patients during the first treatment cycle. Inpatient dose escalation was allowed within protocol-defined limits for individual patients during the dose-escalation portion of the trial.

Choice of Starting Dose

The recommended clinical starting dose of adagrasib was chosen on the basis of the highest nonseverely toxic dose (HNSTD), derived from 28-day GLP dog toxicology studies, with dog as the most sensitive species. With the HNSTD of 25 mg/kg/day, taking one sixth of the HNSTD and correcting for the body surface area equate to a recommended human dose of 2.31 mg/kg/day or 162 mg/day for a 70-kg patient. Thus, 150 mg/day was used as a safe starting dose for this FIH trial.

Choice of First Dosing Regimen

On the basis of a projected human oral $t_{1/2}$ of approximately 15 hours, a once-daily dosing regimen for adagrasib was chosen. The protocol allowed for exploration of alternative dosing regimens during the dose-escalation phase, including twice-a-day dosing or intermittent dosing in 3- or 4-week cycles, depending on the emergent safety/tolerability and PK results.

Patients

Eligible patients were ≥ 18 years old with a histologically confirmed diagnosis of an unresectable or metastatic solid tumor malignancy harboring a *KRAS*^{G12C} mutation in the tumor tissue or circulating tumor DNA on the basis of polymerase chain reaction or next-generation sequencing.

Patients were enrolled using the result from a sponsor-approved or local test, and central confirmation of KRAS^{G12C} before study entry was not required. Key inclusion criteria were measurable or evaluable disease, adequate bone marrow and organ function, an Eastern Cooperative Oncology Group performance status score of ≤ 1 , a life expectancy of at least 3 months, and ability to sign an independent review board–approved informed consent form. Patients' most recent prior systemic therapy and radiation therapy had to be > 2 weeks before the first adagrasib dose. Key exclusion criteria included the presence of active brain metastases or leptomeningeal carcinomatosis. For detailed information on eligibility criteria, see the Data Supplement (online only).

Assessments and End Points

Adverse events (AEs), including clinically significant laboratory abnormalities, were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 reported from the day of the first dose of study treatment until at least 28 days after the last dose.

Patients treated during the dose-escalation phase and selected patients enrolled in dose-expansion cohorts participated in a 96-hour single-dose PK lead-in period. Serial plasma samples for PK evaluation were collected in each patient over 24 hours on specified days after the first dose and during multiple-dose administration.

Baseline disease assessments were performed at screening within 28 days of starting adagrasib using computed tomography or magnetic resonance imaging. On-study disease assessments were performed every 6 weeks after the first dose. Imaging results were evaluated by the investigator to assess disease response as per RECIST 1.1. A best response of complete response/partial response (CR/PR) required a confirmatory assessment at least 4 weeks (≥ 28 days) after the first CR/PR. A best response of stable disease (SD) required a duration of at least 32 days from the date of the first dose; otherwise, it was listed as nonevaluable.

Statistical Analyses

The safety analysis population included all patients who received at least one dose of adagrasib. The PK-evaluable population consisted of all patients who received adagrasib and had adequate and reliable PK data available. Patients who received at least one dose of adagrasib, had an evaluable baseline tumor assessment, and at least one postbaseline tumor assessment were evaluated for clinical response. Descriptive statistics for overall response rate, on the basis of investigator assessment, were analyzed. The time-to-event end points, including duration of response (DOR), progression-free survival (PFS), and overall survival (OS), were reported descriptively and were summarized using the Kaplan-Meier method. Additional details on the statistical analysis can be found in the Data Supplement.

Trial Oversight

This study was approved by an institutional review board at each participating site. The trial was conducted in accordance with Good Clinical Practice guidelines, defined by the International Conference on Harmonization. All patients provided written informed consent before initiation of study procedures.

RESULTS

Patient Demographics and Baseline Characteristics

A total of 25 patients were enrolled and received at least one dose of adagrasib. The cutoff date for this analysis was August 15, 2021, with a median follow-up time for the overall population of 22.8 months (95% CI, 18.7 to 23.4). Patient demographics and baseline characteristics are summarized in Table 1.

TABLE 1. Patient Demographics and Baseline Characteristics

Demographic or Characteristic	All Patients (N = 25)
Median age, years (range)	61 (40-76)
Sex, No. (%)	
Male	10 (40.0)
Female	15 (60.0)
Ethnicity, No. (%)	
White	23 (92.0)
Black or African American	1 (4.0)
Asian	1 (4.0)
ECOG PS, No. (%)	
Grade 0	12 (48.0)
Grade 1	13 (52.0)
Smoking history, No. (%)	
Lifetime nonsmoker	7 (28.0)
Current smoker	0 (0)
Former smoker	18 (72.0)
Primary tumor type, No. (%)	
NSCLC	18 (72.0)
CRC	4 (16.0)
Mucinous appendiceal carcinoma	2 (8.0)
Duodenal adenocarcinoma	1 (4.0)
Stage, No. (%)	
IIIB	2 (8.0)
IV	23 (92.0)
Median No. of prior therapies, NSCLC (range)	3 (0-8)
Median No. of prior therapies, CRC (range)	4 (3-5)
Median No. of prior therapies, others (range)	1 (1-3)

Abbreviations: CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non–small-cell lung cancer.




FIG 1. Disposition of study patients. ^aScreen failures were not distinguished by phase.

Patient Disposition and DLTs

The first four patients enrolled were treated using the AT dose-escalation design, with one patient assigned to each of the four dose levels (150 mg, 300 mg, 600 mg, and 1,200 mg once daily). The numbers of patients assigned to each dose and cohorts are shown in Figure 1, and patient

characteristics by dose levels are summarized in the Data Supplement. No DLTs were observed at the first three dose levels. At 1,200 mg once daily, one patient was determined to have met the criteria for protocol-defined DLT (< 80% dose intensity of cycle 1 doses) because of postdose emesis likely caused by pill burden (12 pills taken at one time). As a




FIG 2. Mean (+SD) plasma adagrasib concentration–time profiles (PK profiles): (A) after a single 600-mg oral dose and (B) after a 600-mg twice-a-day regimen in the steady state under fasting conditions. PK, pharmacokinetics; SD, standard deviation.

result, once daily dose escalation was discontinued, twice-a-day dosing was initiated, and the phase I segment was transitioned from the AT design to the mTPI design. A total of 23 patients were evaluable for DLTs (two patients missed $\geq 20\%$ of their planned dose because of reasons unrelated to adagrasib). Five patients (21.7%) experienced one or more DLTs. The number and nature of DLTs per dose cohort and detailed descriptions of DLTs are provided in the Data Supplement.

PK

Single-dose PK. Adagrasib single-dose exposure increased with increasing doses from 150 mg to 600 mg (Data Supplement). However, assessment of dose proportionality in exposure over the 150- to 600-mg dose range was limited by only one patient enrolled at 150-mg and 300-mg doses. As shown in Figure 2A and Table 2, the median time to reach the maximum plasma concentration (t_{max}) after a single 600-mg oral dose of adagrasib under fasting conditions ($n = 5$) was 4.17 (range, 2-10.10) hours and the arithmetic mean $t_{1/2}$ was 23.0 (range, 16.3-27.9) hours.

Multiple-dose PK. After multiple-dose administration of adagrasib 600 mg twice a day under fasting conditions, the steady state was reached by cycle 1, day 8. The median t_{max} on cycle 1, day 8, was 2.96 (range, 0.48-4.30) hours (Table 2). The geometric mean minimum plasma concentration (C_{min}) on cycle 1, day 8 was 2,693 ng/mL, which exceeded the 1,544-ng/mL target efficacious average concentration derived from observed maximal antitumor efficacy in the least sensitive preclinical xenograft model (Fig 2B; Table 2).⁹ Multiple doses of 600 mg twice a day resulted in an approximately five- to six-fold accumulation of adagrasib and a low peak-to-trough ratio (PTR) of 1.07 in the steady state (Table 2). No additional accumulation of adagrasib was observed after cycle 1, day 8. Compared with the 600-mg twice-a-day regimen, multiple doses of 150 mg and 300 mg once daily resulted in lower drug accumulation (approximately three- to four-fold) and a higher PTR (approximately three) in individual patients (Data Supplement).

Determination of the RP2D

Among the first cohort of six evaluable patients treated at 600 mg twice a day, one patient experienced a DLT. Although the mTPI algorithm recommends dose escalation in this scenario, the sponsor and investigators decided to continue evaluation of 600 mg twice a day, noting that preliminary PK results showed drug concentration levels at or above the predicted efficacious level. Together with two subsequent serial cohorts at the 600-mg twice-a-day dose level, a total of three of the 18 DLT-evaluable patients experienced DLTs. Thus, 600 mg twice a day was chosen as the RP2D.

Safety

Overall, 23 patients (92.0%) experienced treatment-related adverse events (TRAEs), including nine patients (36%) who experienced a grade 3/4 TRAE. The most common TRAEs

TABLE 2. Pharmacokinetics of 600-mg Adagrasib Twice a Day After Single and Multiple Oral Dose Administration Under Fasting Conditions
600 mg Twice a Day

Parameter	No.	gMean (gCV%) ^a
Single dose ^b		
AUC _∞ (h × ng/mL)	5	37,139 (142.2)
C _{max} (ng/mL)	5	984 (94.7)
t _{max} (h)	5	4.17 (2.00-10.10) ^c
t _{1/2} (h)	5	23.0 (16.3)
CL/F (L/h)	5	16.0 (140.8)
V _z /F (L)	5	527 (139.7)
Steady state		
AUC _{τ,ss} (h × ng/mL)	4	31,600 (44.0)
C _{max,ss} (ng/mL)	8	3,253 (36.9)
C _{min,ss} (ng/mL)	8	2,693 (39.1)
t _{max,ss} (h)	8	2.96 (0.48-4.30) ^c
CL/F (L/h)	4	18.8 (45.6)
PTR	8	1.07 (12.9)
R _{ac} (AUC)	4	6.44 (68.6)
R _{ac} (C _{max})	8	5.40 (96.4)

Abbreviations: AUC_{0-∞}, area under the plasma concentration–time curve from time 0 to infinity; AUC_{τ,ss}, area under the plasma concentration–time curve over the dosing interval in the steady state; CL/F, apparent clearance after oral administration, calculated from the quotient dose/AUC_{0-∞}; C_{max}, observed maximum plasma concentration during a sample interval; C_{max,ss}, observed maximum plasma concentration during a sample interval in the steady state; C_{min,ss}, minimum observed concentration during a sampling interval in the steady state; CV, coefficient of variation; gMean, geometric mean; PK, pharmacokinetics; PTR, peak-to-trough ratio; R_{ac} (AUC), accumulation ratio, calculated from AUC_τ at C1D8, relative to AUC_{0-12 h} (for twice-a-day regimen) in the PK lead-in period or at C1D1; R_{ac} (C_{max}), accumulation ratio, calculated from C_{max} at C1D8, relative to C_{max} after the first dose administration; t_{1/2}, terminal elimination half-life; t_{max}, observed time to maximum plasma concentration during a sampling interval; t_{max,ss}, observed time to maximum plasma concentration during a sampling interval in the steady state; V_z/F, apparent volume of distribution during the terminal phase after nonintravenous administration.

^aData reported as geometric mean (geometric mean CV%).
^bSamples for PK analysis were collected from 0 to 96 hours postdose after a single oral dose administration.
^ct_{max} reported as median (min-max).

were nausea (76.0%), diarrhea (72.0%), vomiting (48.0%), and fatigue (40.0%). Among the 20 patients treated at the RP2D of 600 mg twice a day, the most common TRAEs (any grade) were nausea (80.0%), diarrhea (70.0%), vomiting (50.0%), and fatigue (45.0%). The most common grade 3/4 TRAE was fatigue (15.0%). One patient (4.0%) with underlying pneumonitis associated with prior irradiation and systemic therapy experienced treatment-related grade 5 pneumonitis. Thirteen (65.0%) patients

required treatment interruption or dose reduction because of TRAEs. The most common TRAEs leading to treatment interruption or dose reduction at 600 mg twice a day were nausea (25.0%), diarrhea, vomiting, and fatigue (each 20.0%). The median dose compliance was 97.1%, and the median relative dose intensity was 90.8%. Table 3 summarizes the most frequently observed TRAEs for all dose cohorts and at the RP2D.

Antitumor Activity

The evaluation of antitumor activity reported here was by investigator review and included 20 patients enrolled and treated at the RP2D (Data Supplement and Fig 3). Of these 20 patients, the primary diagnosis was *KRAS*^{G12C}-mutant non-small-cell lung cancer (NSCLC; n = 16), *KRAS*^{G12C}-mutant CRC (n = 2), and *KRAS*^{G12C}-mutant mucinous appendiceal carcinoma (n = 2), respectively.

TABLE 3. Summary of TRAEs With an Incidence of $\geq 10\%$ in Either Cohort, or With Grade ≥ 3 Events

TRAE	Any Grade, No. (%)		Grade ≥ 3 , No. (%)	
	Total 600 mg Twice a Day (n = 20)	All Patients (N = 25)	Total 600 mg Twice a Day (n = 20)	All Patients (N = 25)
Nausea	16 (80.0)	19 (76.0)	0 (0)	0 (0)
Diarrhea	14 (70.0)	18 (72.0)	0 (0)	0 (0)
Vomiting	10 (50.0)	12 (48.0)	0 (0)	0 (0)
Fatigue	9 (45.0)	10 (40.0)	3 (15.0)	3 (12.0)
Blood creatinine increased	7 (35.0)	7 (28.0)	0 (0)	0 (0)
AST increased	7 (35.0)	7 (28.0)	1 (5.0)	1 (4.0)
Decreased appetite	7 (35.0)	7 (28.0)	1 (5.0)	1 (4.0)
Skin hyperpigmentation	6 (30.0)	6 (24.0)	0 (0)	0 (0)
Anemia	5 (25.0)	6 (24.0)	1 (5.0)	1 (4.0)
QT prolonged	5 (25.0)	6 (24.0)	0 (0)	1 (4.0)
ALT increased	5 (25.0)	5 (20.0)	1 (5.0)	1 (4.0)
Blood alkaline phosphatase increased	4 (20.0)	4 (16.0)	0 (0)	0 (0)
Dysgeusia	4 (20.0)	4 (16.0)	0 (0)	0 (0)
Lipase increased	4 (20.0)	4 (16.0)	1 (5.0)	1 (4.0)
Abdominal pain	3 (15.0)	3 (12.0)	0 (0)	0 (0)
Peripheral edema	3 (15.0)	3 (12.0)	0 (0)	0 (0)
Pneumonitis	3 (15.0)	3 (12.0)	1 ^a (5.0)	1 ^a (4.0)
Rash	3 (15.0)	3 (12.0)	0 (0)	0 (0)
Decreased weight	3 (15.0)	3 (12.0)	0 (0)	0 (0)
Dizziness	2 (10.0)	3 (12.0)	0 (0)	1 (4.0)
Upper abdominal pain	2 (10.0)	2 (8.0)	0 (0)	0 (0)
Amylase increased	2 (10.0)	2 (8.0)	1 (5.0)	1 (4.0)
Blood creatine phosphokinase increased	2 (10.0)	2 (8.0)	0 (0)	0 (0)
Dry mouth	2 (10.0)	2 (8.0)	0 (0)	0 (0)
Dyspnea	2 (10.0)	2 (8.0)	0 (0)	0 (0)
Decreased cardiac ejection fraction	2 (10.0)	2 (8.0)	0 (0)	0 (0)
Peripheral sensory neuropathy	2 (10.0)	2 (8.0)	0 (0)	0 (0)
Pruritus	2 (10.0)	2 (8.0)	0 (0)	0 (0)
Hyperglycemia	1 (5.0)	1 (4.0)	1 (5.0)	1 (4.0)
Hypokalemia	1 (5.0)	1 (4.0)	1 (5.0)	1 (4.0)
Vertigo	0 (0)	1 (4.0)	0 (0)	1 (4.0)

NOTE. Data cutoff: August 15, 2021; median follow-up: 22.8 months.

Abbreviation: TRAE, treatment-related adverse event.

^aOne patient with a history of chronic radiation-induced pneumonitis died of treatment-related pneumonitis.




FIG 3. (A) Waterfall plot depicting the best tumor change from baseline. (B) Spider plot depicting the change in tumor measurement over time. Clinical activity evaluable population, n = 24; one patient (NSCLC, treated with 600 mg twice a day) was not included due to having no target lesion; therefore, change from baseline cannot be calculated. Data cutoff date: August 15, 2021. CRC, colorectal cancer; NSCLC, non-small-cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease.

At the time of the data cutoff, 15 of 16 patients with *KRAS*^{G12C}-mutant NSCLC at 600 mg twice a day were evaluable for response. After a median follow-up time of 19.6 months, the confirmed overall response rate was 53.3% (95% CI, 26.6 to 78.7; Fig 3) and the median DOR was 16.4+ months (95% CI, 3.1 to not estimable; range, 2.8-16.9 months). Two responses occurred in later cycles in patients who had been receiving treatment for longer than 10 months. Four patients had ongoing responses with

durations of 16.9, 12.6, 5.4, and 2.8 months, respectively, at the time of the data cutoff (Fig 3).

Among the 16 patients with *KRAS*^{G12C}-mutant NSCLC enrolled and treated at the RP2D, the median PFS was 11.1 months (95% CI, 2.6 to not estimable; range, 0-22.4+ months). Kaplan-Meier estimates of PFS at 6 and 12 months were 64.3% (95% CI, 34.3 to 83.3) and 50.0% (95% CI, 22.9 to 72.2), respectively (Data Supplement). The median OS was NR (95% CI, 3.1 to not estimable) and

ranged from 2.1 to 23.4+ months (Data Supplement). OS rates for these patients at 6 and 12 months were 73.3% (95% CI, 43.6 to 89.1) and 66.7% (95% CI, 37.5 to 84.6), respectively. Nine of the 16 patients were alive at the time of the data cutoff on August 15, 2021, including five patients who were still receiving treatment.

In addition, a confirmed PR was observed in one of the two patients with *KRAS*^{G12C}-mutant CRC at the 600-mg twice-a-day dose, with a DOR of 4.2 months. SD was reported in the two patients with mucinous appendiceal carcinoma (Fig 3). One patient with metastatic *KRAS*^{G12C}-mutant appendiceal adenocarcinoma and peritoneal carcinomatosis achieved a significant biochemical response, characterized by a decrease in the carcinoembryonic antigen level from a pre-treatment baseline of 509 ng/mL to < 5 ng/mL; this patient had a duration of disease control of 24.8 months at the time of the data cutoff.

PFS durations for the two patients with *KRAS*^{G12C}-mutant CRC treated at the 600-mg twice-a-day dose were 3.3 and 5.5 months, respectively. OS durations for these two patients were 9.5 months and 10.5 months, respectively. PFS durations for the two patients with *KRAS*^{G12C}-mutant mucinous appendiceal carcinoma were 8.3 months and 24.8 months, respectively. At the time of the data cutoff, OS durations for these two patients were 23.2 and 26.2 months, respectively, and both patients were still alive. Among the five patients who began treatment at other dose levels, four achieved SD and one had PD as a best response (Fig 3).

DISCUSSION

This FIH, phase I/IB study demonstrated that adagrasib, a highly selective and potent oral small-molecule inhibitor of *KRAS*^{G12C}, was well tolerated and showed evidence of clinical activity at 600 mg twice a day in patients with advanced solid tumors harboring the *KRAS*^{G12C} mutation.

In the current study, adagrasib exhibited favorable PK properties, including oral bioavailability, long $t_{1/2}$ (approximately 24 hours), extensive tissue distribution (apparent volume of distribution: 527 L), and sustained plasma concentrations, as evidenced by a relatively flat plasma concentration–time profile and low PTR variability.⁹ The dose-dependent PK and preliminary clinical activity of adagrasib support its ongoing evaluation as both monotherapy and in selected combination therapy strategies.

Studies conducted in nonclinical tumor models have indicated that maintaining plasma concentrations above the target threshold for the full-dose interval is important for maximizing antitumor efficacy, as new protein synthesis can result in uninhibited *KRAS*^{G12C} in the absence of adequate

levels of inhibitor.⁹ The sustained exposure of adagrasib above the target threshold over the entire dosing interval at the 600-mg twice-a-day dose level is predicted to enable inhibition of newly synthesized *KRAS*^{G12C} and prevent a rebound in *KRAS*-dependent extracellular signal–regulated kinase signaling—a critical factor for durable antitumor activity.⁹

During the dose escalation (single patient AT design) in this study, a DLT of capsule burden intolerance was observed at 1,200 mg once daily (involving twelve 100 mg pills). Consequently, 600-mg twice-a-day dosing was selected for the phase Ib expansion and ultimately for the phase II expansion because of the desired observed safety and PK and initial signs of efficacy. In addition, on the basis of preclinical modeling, 600-mg twice-a-day PK data have shown that exposure of adagrasib at the steady state dose is 2-fold above the exposure required for a maximal response in the least sensitive animal models, whereas once daily dosing only achieved exposure above that required for maximal responses in the more sensitive preclinical models.

During the study, 65% of patients had treatment interruption or reduction because of TRAEs, which were primarily gastrointestinal in nature and included diarrhea, nausea, or vomiting. These TRAEs were generally low grade, occurred early in treatment, and typically resolved on their own (with occasional prophylaxis—eg, primarily prochlorperazine for nausea/vomiting and loperamide as an option for diarrhea). Although the mechanism of the gastrointestinal AEs is not currently known, the presentation was consistent with local irritation that might have resulted from the capsule formulation. In normal healthy volunteers, data suggest a lower rate of gastrointestinal AEs with a tablet formulation after a single dose [data on file]; the safety of the tablet is being further explored in KRYSTAL-1 (ClinicalTrials.gov identifier: [NCT03785249](https://clinicaltrials.gov/ct2/show/study/NCT03785249)) and in the Expanded Access Program (ClinicalTrials.gov identifier: [NCT05162443](https://clinicaltrials.gov/ct2/show/study/NCT05162443)).

On the basis of these encouraging phase I/II results, two pivotal registration-enabling phase III clinical trials are ongoing. KRYSTAL-12 compares adagrasib with docetaxel in previously treated *KRAS*^{G12C}-mutant NSCLC (ClinicalTrials.gov identifier: [NCT04685135](https://clinicaltrials.gov/ct2/show/study/NCT04685135)); KRYSTAL-10 compares adagrasib in combination with cetuximab versus chemotherapy in the second-line treatment of *KRAS*^{G12C}-mutant CRC (ClinicalTrials.gov identifier: [NCT04793958](https://clinicaltrials.gov/ct2/show/study/NCT04793958)). In addition, trials evaluating adagrasib as monotherapy or in combination with other agents in *KRAS*^{G12C}-mutant NSCLC, CRC, and other solid tumors are ongoing (KRYSTAL-2 [ClinicalTrials.gov identifier: [NCT04330664](https://clinicaltrials.gov/ct2/show/study/NCT04330664)], KRYSTAL-7 [ClinicalTrials.gov identifier: [NCT04613596](https://clinicaltrials.gov/ct2/show/study/NCT04613596)], and KRYSTAL-14 [ClinicalTrials.gov identifier: [NCT04975256](https://clinicaltrials.gov/ct2/show/study/NCT04975256)]).

AFFILIATIONS

¹University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center, Orange, CA

²Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

³University of Wisconsin Carbone Cancer Center, Madison, WI

⁴Henry Ford Cancer Institute, Detroit, MI

⁵Perlmutter Cancer Center New York University Langone Health, New York, NY

⁶Mary Crowley Cancer Center, Dallas, TX

⁷University of California San Diego, Moores Cancer Center, La Jolla, CA

⁸Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN

⁹Mirati Therapeutics, Inc, San Diego, CA

¹⁰START San Antonio, San Antonio, TX

CORRESPONDING AUTHOR

Sai-Hong Ignatius Ou, MD, PhD, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, 200 South Manchester Ave, Suite 400, Orange, CA 92868; e-mail: siou@hs.uci.edu.

PRIOR PRESENTATION

Presented previously at the 2020 EORTC-NCI-AACR (ENA) Virtual Symposium, October 24-25, 2020.

SUPPORT

Support for this study was provided by Mirati Therapeutics, Inc. Medical writing and editorial support were provided by Caleb Rans and Ellen Powers of Axiom Healthcare Strategies (Princeton, NJ).

CLINICAL TRIAL INFORMATION

[NCT03785249](https://clinicaltrials.gov/ct2/show/study/NCT03785249)

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.21.02752>.

DATA SHARING STATEMENT

Mirati will honor legitimate requests for clinical trial data from qualified researchers, upon request, as necessary for conducting methodologically

sound research. Mirati will provide access to data and clinical study reports (CSRs) for clinical trials for which results are posted on the clinicaltrials.gov registry for products or indications that have been approved by regulators in the United States and European Union. In general, data will be made available for request approximately 12 months after clinical trial completion. Relevant components of the protocol and statistical analysis plan for the KRYSTAL-1 study will also be made available upon request.

AUTHOR CONTRIBUTIONS

Conception and design: Sai-Hong Ignatius Ou, Pasi A. Jänne, Melissa L. Johnson, Cornelius Cilliers, James G. Christensen, Xiaohong Yan, Richard C. Chao, Kyriakos P. Papadopoulos

Administrative support: Karen L. Velastegui

Provision of study materials or patients: Sai-Hong Ignatius Ou, Pasi A. Jänne, Ticiania A. Leal, Igor I. Rybkin, Joshua K. Sabari, Minal A. Barve, Lyudmila Bazhenova, Melissa L. Johnson, James G. Christensen, Richard C. Chao, Kyriakos P. Papadopoulos

Collection and assembly of data: All authors

Data analysis and interpretation: Sai-Hong Ignatius Ou, Pasi A. Jänne, Ticiania A. Leal, Igor I. Rybkin, Joshua K. Sabari, Minal A. Barve, Lyudmila Bazhenova, Melissa L. Johnson, Cornelius Cilliers, James G. Christensen, Xiaohong Yan, Richard C. Chao, Kyriakos P. Papadopoulos

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

We thank the patients, their families, and their caregivers, and the study investigators and their team members at each site for participation in the ongoing KRYSTAL-1 trial. Dr Sai-Hong Ignatius Ou wrote and edited the first version of the manuscript. All the authors reviewed, revised, and approved the final manuscript.

REFERENCES

- Zehir A, Benayed R, Shah RH, et al: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med* 23:703-713, 2017
- Ostrem JM, Shokat KM: Direct small-molecule inhibitors of KRAS: From structural insights to mechanism-based design. *Nat Rev Drug Discov* 15:771-785, 2016
- Simanshu DK, Nissley DV, McCormick F: RAS proteins and their regulators in human disease. *Cell* 170:17-33, 2017
- Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 487:330-337, 2012
- Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 511:543-550, 2014
- Christensen JG, Olson P, Briere T, et al: Targeting Kras(g12c)-mutant cancer with a mutation-specific inhibitor. *J Intern Med* 288:183-191, 2020
- Hu Q, Shokat KM: Disease-causing mutations in the G protein Galphas subvert the roles of GDP and GTP. *Cell* 173:1254-1264 e11, 2018
- Hong DS, Fakhri MG, Strickler JH, et al: KRAS(G12C) inhibition with sotorasib in advanced solid tumors. *N Engl J Med* 383:1207-1217, 2020
- Hallin J, Engstrom LD, Hargis L, et al: The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. *Cancer Discov* 10:54-71, 2020
- Lito P, Solomon M, Li LS, et al: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. *Science* 351:604-608, 2016



AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^{G12C} Solid Tumors (KRYSTAL-1)

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

Sai-Hong Ignatius Ou

Stock and Other Ownership Interests: Turning Point Therapeutics, Elevation Oncology

Honoraria: Pfizer, Roche Pharma AG, Genentech/Roche, ARIAD/Takeda, AstraZeneca, BeiGene

Consulting or Advisory Role: Pfizer, Roche/Genentech, AstraZeneca, Takeda, Janssen/JNJ

Speakers' Bureau: AstraZeneca, Genentech/Roche

Research Funding: Pfizer (Inst), Roche Pharma AG (Inst), AstraZeneca/MedImmune (Inst), AstraZeneca (Inst), ARIAD (Inst), Revolution Medicines (Inst), Mirati Therapeutics (Inst), Janssen/JNJ (Inst)

Pasi A. Jänne

Stock and Other Ownership Interests: Gatekeeper Pharmaceuticals, Loxo Oncology

Consulting or Advisory Role: Pfizer, Boehringer Ingelheim, AstraZeneca, Merrimack, Chugai Pharma, Roche/Genentech, LOXO, Mirati Therapeutics, Araxes Pharma, Ignyta, Lilly, Takeda, Novartis, Biocartis, Voronoi, SFJ Pharmaceuticals Group, Sanofi, Daiichi Sankyo, Silicon Therapeutics, Nuvalent, Inc, Eisai, Bayer, Syndax, AbbVie, Allorion Therapeutics, Accutar Biotech, Transcenta

Research Funding: AstraZeneca, Astellas Pharma, Daiichi Sankyo, Lilly, Boehringer Ingelheim, Puma Biotechnology, Takeda, Revolution Medicines

Patents, Royalties, Other Intellectual Property: I am a coinventor of a DFCl-owned patent on EGFR mutations licensed to Lab Corp. I receive postmarketing royalties from this invention

Ticiana A. Leal

Consulting or Advisory Role: Takeda, Jazz Pharmaceuticals, AstraZeneca, EMD Serono, Merck, Boehringer Ingelheim, Blueprint Medicines, Daiichi Sankyo/Lilly, Bayer, Genentech, Lilly, Janssen, Mirati Therapeutics, Daiichi-Sankyo, Eisai, Daiichi Sankyo/AstraZeneca, Novocure

Igor I. Rybkin

Consulting or Advisory Role: AstraZeneca

Joshua K. Sabari

Consulting or Advisory Role: AstraZeneca, Janssen Oncology, Navire, Pfizer, Regeneron, Medscape, Takeda

Minal A. Barve

Employment: Texas Oncology

Stock and Other Ownership Interests: Texas Oncology

Research Funding: Mary Crowley Research Center

Lyudmila Bazhenova

Stock and Other Ownership Interests: Epic Sciences

Consulting or Advisory Role: Genentech/Roche, Boehringer Ingelheim, Novartis, Regeneron, Merck, Johnson and Johnson, BMSi, Daichi, NEUVOGEN, Bayer, Sanofi, ORCIC, Turning Point Therapeutics

Research Funding: BeyondSpring Pharmaceuticals

Melissa L. Johnson

Employment: HCA Healthcare

Consulting or Advisory Role: Otsuka, Genentech/Roche (Inst), Boehringer Ingelheim (Inst), AstraZeneca (Inst), Calithera Biosciences (Inst), Merck (Inst), Loxo (Inst), Sanofi (Inst), Mirati Therapeutics (Inst), Pfizer (Inst), Guardant Health (Inst), Ribon Therapeutics (Inst), Incyte (Inst), AbbVie (Inst), Achilles Therapeutics (Inst), Atreca (Inst), GlaxoSmithKline (Inst), Gritstone Oncology (Inst), Janssen Oncology (Inst), Lilly (Inst), Novartis (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), G1 Therapeutics (Inst), WindMIL (Inst), Checkpoint Therapeutics (Inst), Eisai (Inst), Axelia Oncology (Inst), Black Diamond Therapeutics (Inst), CytomX Therapeutics (Inst), EcoR1 Capital (Inst), Editas Medicine (Inst), Genmab (Inst), IDEAYA Biosciences (Inst), ITeos Therapeutics (Inst), Oncorus (Inst), Regeneron (Inst), Turning Point Therapeutics (Inst)

Research Funding: EMD Serono (Inst), Kadmon (Inst), Janssen (Inst), Mirati Therapeutics (Inst), Genmab (Inst), Pfizer (Inst), AstraZeneca (Inst), Stencenrx

(Inst), Novartis (Inst), Checkpoint Therapeutics (Inst), Array BioPharma (Inst), Regeneron (Inst), Merck (Inst), Hengrui Pharmaceutical (Inst), Lycera (Inst), BeiGene (Inst), Tarveda Therapeutics (Inst), Loxo (Inst), AbbVie (Inst), Boehringer Ingelheim (Inst), Guardant Health (Inst), Daiichi Sankyo (Inst), Sanofi (Inst), CytomX Therapeutics (Inst), Dynavax Technologies (Inst), Corvus Pharmaceuticals (Inst), Incyte (Inst), Genocoea Biosciences (Inst), Gritstone Oncology (Inst), Amgen (Inst), Genentech/Roche (Inst), Adaptimmune (Inst), Syndax (Inst), Neovia Oncology (Inst), Acerta Pharma (Inst), Takeda (Inst), Shattuck Labs (Inst), GlaxoSmithKline (Inst), Apexigen (Inst), Atreca (Inst), OncoMed (Inst), Lilly (Inst), Immunocore (Inst), Jounce Therapeutics (Inst), University of Michigan (Inst), WindMIL (Inst), TCR2 Therapeutics (Inst), Arcus Biosciences (Inst), Ribon Therapeutics (Inst), BerGenBio (Inst), Calithera Biosciences (Inst), Tmunity Therapeutics, Inc (Inst), Seven and Eight Biopharmaceuticals (Inst), Rubius Therapeutics (Inst), Curis (Inst), Silicon Therapeutics (Inst), Dracen (Inst), PMV Pharma (Inst), Artios (Inst), BioAtla (Inst), Elicio Therapeutics (Inst), Erasca, Inc (Inst), Harpoon (Inst), Helsinn Healthcare (Inst), Hutchison MediPharma (Inst), IDEAYA Biosciences (Inst), IGM Biosciences (Inst), Memorial Sloan-Kettering Cancer Center (Inst), NeolmmuneTech (Inst), Numab (Inst), RasCal (Inst), Relay Therapeutics (Inst), Revolution Medicines (Inst), Tempest Therapeutics (Inst), Tizona Therapeutics, Inc (Inst), Turning Point Therapeutics (Inst), Vyriad (Inst), Y-mAbs Therapeutics (Inst)

Travel, Accommodations, Expenses: AbbVie, AstraZeneca, Genentech, Incyte, Merck, Pfizer, Sanofi

Karen L. Velastegui

Employment: Mirati Therapeutics, Arena Pharma

Stock and Other Ownership Interests: Mirati Therapeutics, Arena Pharma

Cornelius Cilliers

Employment: Mirati Therapeutics

Stock and Other Ownership Interests: Mirati Therapeutics

James G. Christensen

Employment: Mirati Therapeutics

Leadership: Mirati Therapeutics

Stock and Other Ownership Interests: Mirati Therapeutics

Consulting or Advisory Role: BridgeBio Pharma

Patents, Royalties, Other Intellectual Property: Multiple patents in the last 2 years while employed at Mirati Therapeutics covering discovery of KRAS, LSD1, and EZH2 inhibitors (Inst)

Xiaohong Yan

Employment: Mirati Therapeutics

Stock and Other Ownership Interests: Mirati Therapeutics

Travel, Accommodations, Expenses: Mirati Therapeutics

Richard C. Chao

Employment: Mirati Therapeutics

Stock and Other Ownership Interests: Mirati Therapeutics, Pfizer, Merck

Kyriakos P. Papadopoulos

Consulting or Advisory Role: Basilea, Turning Point Therapeutics, Bicycle Therapeutics

Research Funding: AbbVie (Inst), MedImmune (Inst), Daiichi Sankyo (Inst), Regeneron (Inst), Amgen (Inst), Calithera Biosciences (Inst), Incyte (Inst), Merck (Inst), Peloton Therapeutics (Inst), ADC Therapeutics (Inst), 3D Medicines (Inst), EMD Serono (Inst), Syros Pharmaceuticals (Inst), Mersana (Inst), MabSpace Biosciences (Inst), Jounce Therapeutics (Inst), Bayer (Inst), AnHeart Therapeutics (Inst), F-star (Inst), Linnaeus Therapeutics (Inst), Mirati Therapeutics (Inst), Tempest Therapeutics (Inst), Treadwell Therapeutics (Inst), Lilly (Inst), Pfizer (Inst), BioNTech (Inst), Bicycle Therapeutics (Inst), Kezar Life Sciences (Inst)

No other potential conflicts of interest were reported.